Pharmaceuticals: Restrictions in Use and Availability
(2001; 40 pages) View the PDF document
Table of Contents
Open this folder and view contentsIntroduction
Close this folderMonocomponent products
View the documentAlatrofloxacin mesilate
View the documentAldesleukin
View the documentAmineptine
View the documentAmfepramone hydrochloride
View the documentAristolochia
View the documentAstemizole
View the documentBromfenac
View the documentBuprenorphine
View the documentBuspirone hydrochloride
View the documentCamphor
View the documentChlormezanone
View the documentCisapride
View the documentDantron
View the documentDequalinium
View the documentDexfenfluramine hydrochloride
View the documentDiphenoxylate
View the documentDoxycycline hydrochloride (capsules)
View the documentDronabinol
View the documentEbrotidine
View the documentEpoetin alfa and epoetin beta
View the documentErythrityl tetranitrate
View the documentFenfluramine
View the documentFlunitrazepam
View the documentFurazolidone
View the documentGentamicin (topical preparations)
View the documentGrepafloxacin hydrochloride
View the documentGinkgo biloba
View the documentKetamine hydrochloride
View the documentKetorolac
View the documentLamivudine
View the documentLevamisole hydrochloride
View the documentLexipafant
View the documentLoxoprofen sodium
View the documentMedifoxamine
View the documentMepacrine
View the documentMetamizole sodium
View the documentMethylrosanilinium chloride
View the documentMetoclopramide (paediatric)
View the documentMibefradil
View the documentMisoprostol
View the documentNandrolone
View the documentOxeladin citrate
View the documentPexiganan
View the documentPhenolphthalein
View the documentPhentermine
View the documentPhentolamine mesilate
View the documentPhenylbutazone
View the documentPiperazine
View the documentPromethazine
View the documentProxibarbal
View the documentPyrithione zinc
View the documentPumactant
View the documentRituximab
View the documentSertindole
View the documentSibutramine
View the documentSulfaguanidine
View the documentTerfenadine
View the documentTilbroquinol
View the documentTolcapone
View the documentTramadol
View the documentTroglitazone
View the documentTrovafloxacin mesilate
View the documentZopiclone
Open this folder and view contentsCombination Products
Open this folder and view contentsGroup Products

Metamizole sodium

Product name:

Metamizole sodium

CAS number:



Dipyrone; Noramidopyrine methanesulfonate sodium; Methanesulfonic acid,[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl) methylamino]-, sodium salt


Effective Date

Description of action taken
Grounds for decision


February 2000

The Drug and Medical Technology Agency has suspended the marketing authorization of metamizole sodium (tablets and solution). The decision is based on a large number of reports on agranulocytosis in Sweden since 1996 and other dangerous adverse effects. (Reference: Communication to WHO, 9 August 2000.)


June 2000

The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in Colombia, Colombian Ministry of Health has restricted the use of metamizole either alone or in combination. These products should be available only if other therapeutic management is insufficient. (Reference: Resolucion No. 259048, INVIMA, 22 June 2000, Ministerio de Salud.)


May 2000

The Minister of Public Health has decided to suspend the marketing authorization for products containing metamizole sodium on the recommendation of the National Advisory Commission for Pharmacovigilance. This recommendation followed an official survey which showed severe adverse reactions associated with this product. (Reference: Letter from the Direction du médicament et de la pharmacie, Rabat, 8 September 2000.)



The Medical Products Agency has suspended the marketing authorization for metamizole sodium with effect from 28 April 1999. The decision is based on a larger than expected number of reports of agranulocytosis in Sweden since 1996 (1 in 1,700). (References: EU/EEA Rapid Alert, Läkemedelsverket (Medical Products Agency), 28 April 1999.)



The Suprim Technical Committee and the Ministry of Health has instructed all local drug factories to stop manufacturing metamizole sodium (dipyrone) ampoules with immediate effect. (Reference: Announcement from the Directorate No: 1784 dated 2/2/98.)



The Supreme Board of Drugs and Medical Appliances has withdrawn all formulations of metamizole sodium because of its potential to cause anaphylactic shock and agranulocytosis. (Reference: Communications from WHO Representative, Yemen, 17 December and 10 October 1998.)



The Medicines Control Authority has cancelled the registration of all metamizole sodium (dipyrone)- containing products due to the potential risk of metamizole sodium causing fatal agranulocytosis. (Reference: Drug Information Bulletin Vol.2, No.1, March 1998.)

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017